Analysis of cytokines in tear fluid from atopic dermatitis patients with dupilumab-associated ocular adverse events.

Date publication

octobre 2021

Journal

Journal of the European Academy of Dermatology and Venereology : JEADV

Auteurs

Membres identifiés du Cancéropôle Est :
Pr AUBIN François

Tous les auteurs :
Vuillemey L, Febvay C, Puzenat E, Bellanger AP, Chague C, Puyraveau M, Delbosc B, Gauthier AS, Aubin F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34626023

Résumé

Although the introduction of dupilumab has revolutionized the management of atopic dermatitis (AD), dupilumab-associated ocular adverse events (DAOAE) represent the first cause for discontinuation of dupilumab. The exact pathogenesis of DAOAE events observed is unknown. We conducted a prospective study from October 2019 to June 2020 to determine the feasibility of cytokine analysis in tear fluid obtained by non-invasive capillarity from AD patients treated with dupilumab and to compare the inflammatory cytokine profiles before and during dupilumab treatment between patients with and without DAOAE.

Mots clés

atopic dermatitis, cytokines, dupilumab, ocular adverse event, tear fluid

Référence

J Eur Acad Dermatol Venereol. 2021 Oct 8;: